Literature DB >> 31617248

Validation and development of the CHAARTED criteria in patients with hormone-naïve metastatic prostate cancer: A multi-institutional retrospective study in Japan.

Teppei Okamoto1, Shingo Hatakeyama1, Shintaro Narita2, Yoichi Arai3, Tomonori Habuchi2, Chikara Ohyama1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31617248     DOI： 10.1111/iju.14136

Source DB:  PubMed          Journal:  Int J Urol        ISSN： 0919-8172            Impact factor:   3.369


× No keyword cloud information.
  7 in total

Review 1.  Narrative review of urinary glycan biomarkers in prostate cancer.

Authors:  Shingo Hatakeyama; Tohru Yoneyama; Yuki Tobisawa; Hayato Yamamoto; Chikara Ohyama
Journal:  Transl Androl Urol       Date:  2021-04

2.  Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naïve Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese Multi-Institutional Study.

Authors:  Takashi Kawahara; Shuko Yoneyama; Yoshio Ohno; Junpei Iizuka; Yasunobu Hashimoto; Hideyasu Tsumura; Ken-Ichi Tabata; Yoshihiro Nakagami; Kazunari Tanabe; Masatsugu Iwamura; Hiroji Uemura; Yasuhide Miyoshi
Journal:  Biomed Res Int       Date:  2020-07-01       Impact factor: 3.411

3.  Utility of plasma cell-free DNA in metastatic castration-resistant prostate cancer.

Authors:  Itsuto Hamano; Shingo Hatakeyama; Tomoko Hamaya; Kyo Togashi; Teppei Okamoto; Hayato Yamamoto; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Chikara Ohyama
Journal:  IJU Case Rep       Date:  2020-06-07

4.  Therapeutic effects of the combined androgen blockade therapy versus luteinizing hormone-releasing hormone analog monotherapy in patients with hormone naïve metastatic prostate cancer: a multi-institutional comparative analysis.

Authors:  Takuma Narita; Shingo Hatakeyama; Shintaro Narita; Masahiro Takahashi; Toshihiko Sakurai; Sadafumi Kawamura; Senji Hoshi; Jiro Shimoda; Toshiaki Kawaguchi; Shigeto Ishidoya; Koji Mitsuzuka; Yoichi Arai; Akihiro Ito; Norihiko Tsuchiya; Tomonori Habuchi; Chikara Ohyama
Journal:  Transl Androl Urol       Date:  2021-01

5.  Frailty is a predictor of moderate to severe pain after robot-assisted laparoscopic prostatectomy: A case-control study (FRAP study).

Authors:  Masaki Momota; Shingo Hatakeyama; Osamu Soma; Itsuto Hamano; Naoki Fujita; Teppei Okamoto; Kyo Togashi; Tomoko Hamaya; Tohru Yoneyama; Hayato Yamamoto; Takahiro Yoneyama; Yasuhiro Hashimoto; Chikara Ohyama
Journal:  BJUI Compass       Date:  2020-05-14

6.  Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study.

Authors:  Teppei Okamoto; Daisuke Noro; Shingo Hatakeyama; Shintaro Narita; Koji Mitsuzuka; Toshihiko Sakurai; Sadafumi Kawamura; Senji Hoshi; Jiro Shimoda; Toshikazu Tanaka; Toshiaki Kawaguchi; Shigeto Ishidoya; Akihiro Ito; Norihiko Tsuchiya; Tomonori Habuchi; Chikara Ohyama
Journal:  BMC Cancer       Date:  2021-05-25       Impact factor: 4.430

7.  Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients.

Authors:  Masaki Shiota; Naoki Terada; Toshihiro Saito; Akira Yokomizo; Naoki Kohei; Takayuki Goto; Sadafumi Kawamura; Yasuhiro Hashimoto; Atsushi Takahashi; Takahiro Kimura; Ken-Ichi Tabata; Ryotaro Tomida; Kohei Hashimoto; Toshihiko Sakurai; Toru Shimazui; Shinichi Sakamoto; Manabu Kamiyama; Nobumichi Tanaka; Koji Mitsuzuka; Takuma Kato; Shintaro Narita; Hiroaki Yasumoto; Shogo Teraoka; Masashi Kato; Takahiro Osawa; Yoshiyuki Nagumo; Hiroaki Matsumoto; Hideki Enokida; Takayuki Sugiyama; Kentaro Kuroiwa; Takahiro Inoue; Takashi Mizowaki; Toshiyuki Kamoto; Takahiro Kojima; Hiroshi Kitamura; Mikio Sugimoto; Hiroyuki Nishiyama; Masatoshi Eto
Journal:  Cancer Sci       Date:  2021-02-13       Impact factor: 6.716
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.